| Autor: |
Ursenbach, Axel, Ruch, Yvon, Hoellinger, Baptiste, Fuchs, Anne, Caspar, Stéphanie, Jegou, Frédérick, Rey, David, Fafi-Kremer, Samira, Mesplède, Thibault, Gantner, Pierre |
| Předmět: |
|
| Zdroj: |
Clinical Infectious Diseases; 7/15/2024, Vol. 79 Issue 1, p198-201, 4p |
| Abstrakt: |
Dolutegravir/lamivudine (DTG/3TC) has a high genetic barrier against the development of human immunodeficiency virus drug resistance. We report 2 cases of R263K + M184V mutations during DTG/3TC failure followed by viral suppression after adherence intervention without treatment change that we attribute to residual drug activity, reduced viral fitness, and robust immune competence. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
